EDGAR Filing Documents for 0001104659-19-042162

Form 8-K - Current report:

SEC Accession No. 0001104659-19-042162

Filing Date

2019-07-29

Accepted

2019-07-29 07:05:41

Documents

Period of Report

2019-07-25

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	a19-16243_18k.htm	8-K	40217
2	EX-10.1	a19-16243_1ex10d1.htm	EX-10.1	64380
3	EX-10.2	a19-16243_1ex10d2.htm	EX-10.2	107117
4	EX-10.3	a19-16243_1ex10d3.htm	EX-10.3	117734
5	EX-10.4	a19-16243_1ex10d4.htm	EX-10.4	95548
6	EX-10.5	a19-16243_1ex10d5.htm	EX-10.5	91478
7	EX-99.1	a19-16243_1ex99d1.htm	EX-99.1	15009
8	GRAPHIC	g162431mmi001.jpg	GRAPHIC	2594
	Complete submission text file	0001104659-19-042162.txt		536524

Mailing Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038

Business Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038 (212) 332-3241

Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)